+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biosimulation Technology: Global Strategic Business Report

  • PDF Icon

    Report

  • 214 Pages
  • December 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 3440921

Quick Summary:

In the rapidly evolving world of biological sciences, the need for in-depth knowledge and predictive power can make all the difference. The global Biosimulation Technology market is quickly emerging as a fundamental tool, offering invaluable insights for strategic decision-making and operational efficiency enhancement.

Our comprehensive market research report dives into the core of this groundbreaking technology, providing the key data needed to set a course for success. We meticulously track the factors shaping this field, breaking down the market into understandable segments, and putting the market dynamics into context. Our report sheds light on the shifting landscapes in key regions like the U.S., China, Japan, Canada, and Germany, mapping out growth trajectories and crucial trends.

Further, the report highlights notable competitors, enabling a straightforward assessment of the competition's strengths. From cutting-edge industry breakthroughs to socio-economic impacts and future predictions, our Biosimulation Technology market research report is your ticket to staying ahead of the curve in this burgeoning sector.

Global Biosimulation Technology Market to Reach $7.6 Billion by 2030

The global market for Biosimulation Technology estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$7.6 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2022-2030. Software, one of the segments analyzed in the report, is projected to record 14.9% CAGR and reach US$5.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Services segment is readjusted to a revised 17.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $690.8 Million, While China is Forecast to Grow at 14.7% CAGR

The Biosimulation Technology market in the U.S. is estimated at US$690.8 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 14.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.3% and 13.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11.3% CAGR.

Select Competitors (Total 22 Featured) -

  • 3DS BIOVIA
  • Advanced Chemistry Development, Inc. (ACD/Labs)
  • Certara USA, Inc.
  • Genedata AG
  • Schrodinger LLC

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Biosimulation Technology

What is the estimated value of the Global Market for Biosimulation Technology?

The Global Market for Biosimulation Technology was estimated to be valued at $2.4 Billion in 2022.

What is the growth rate of the Global Market for Biosimulation Technology?

The growth rate of the Global Market for Biosimulation Technology is 15.5%, with an estimated value of $7.6 Billion by 2030.

What is the forecasted size of the Global Market for Biosimulation Technology?

The Global Market for Biosimulation Technology is estimated to be worth $7.6 Billion by 2030.

Who are the key companies in the Global Market for Biosimulation Technology?

Key companies in the Global Market for Biosimulation Technology include 3DS BIOVIA, Advanced Chemistry Development, Inc. (ACD/Labs), Certara USA, Inc., Genedata AG and Schrodinger LLC.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Biosimulation Technology - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
  • Table 3: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 4: World 8-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 6: World 8-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World 8-Year Perspective for Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 9: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 10: World 8-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 12: World 8-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Regulatory Authorities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World 8-Year Perspective for Regulatory Authorities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 15: World Recent Past, Current & Future Analysis for Academic Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 16: World 8-Year Perspective for Academic Research Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 18: World 8-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World 8-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
  • Table 21: World Biosimulation Technology Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 22: USA Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 23: USA 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 24: USA Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 25: USA 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 26: USA Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 27: USA 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
CANADA
  • Table 28: Canada Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 29: Canada 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 30: Canada Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 31: Canada 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 32: Canada Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: Canada 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
JAPAN
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 34: Japan Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 35: Japan 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 36: Japan Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 37: Japan 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 38: Japan Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Japan 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
CHINA
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 40: China Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 41: China 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 42: China Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 43: China 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 44: China Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: China 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
EUROPE
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 46: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 47: Europe 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
  • Table 48: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 49: Europe 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Europe 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 52: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 53: Europe 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
FRANCE
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 54: France Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 55: France 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 56: France Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: France 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 58: France Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 59: France 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
GERMANY
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 60: Germany Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 61: Germany 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 62: Germany Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: Germany 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 64: Germany Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 65: Germany 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
ITALY
  • Table 66: Italy Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 67: Italy 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 68: Italy Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: Italy 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 70: Italy Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 71: Italy 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
UNITED KINGDOM
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 72: UK Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 73: UK 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 74: UK Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: UK 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 76: UK Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 77: UK 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
REST OF EUROPE
  • Table 78: Rest of Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 79: Rest of Europe 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: Rest of Europe 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 82: Rest of Europe Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 83: Rest of Europe 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
ASIA-PACIFIC
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 84: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 85: Asia-Pacific 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Asia-Pacific 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 88: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 89: Asia-Pacific 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
REST OF WORLD
  • Table 90: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 91: Rest of World 8-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2023 & 2030
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Rest of World 8-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2023 & 2030
  • Table 94: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 95: Rest of World 8-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2023 & 2030
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3DS BIOVIA
  • Advanced Chemistry Development, Inc. (ACD/Labs)
  • Certara USA, Inc.
  • Genedata AG
  • Schrodinger LLC